LakeShore Biopharma Gets Non-Binding Acquisition Offer from Oceanpine
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 18 2025
0mins
Acquisition Proposal: LakeShore Biopharma's board received a non-binding proposal from Oceanpine Investment Fund II LP and Oceanpine Capital to acquire all outstanding ordinary shares not owned by Oceanpine Capital for 86 cents per share.
Premium Offer: The proposed price represents a 10.3% premium over the last closing price on August 15 and an 11.4% premium over the average closing price during the previous 15 trading days.
Funding Details: Oceanpine Capital plans to finance the transaction using rollover equity and available cash, with no financing condition attached.
Board Review: The board will carefully evaluate the proposal to determine the best course of action for the company and its shareholders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
